Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

MPI – Notice of Extraordinary General Meeting in Medical Prognosis Institute A/S

Regulatory

MPI – Indkaldelse til ekstraordinær generalforsamling i Medical Prognosis Institute A/S

Regulatory

Medical Prognosis Institute A/S – Interim Report First Half 2014

Regulatory

MPI advances the date for publication of its scheduled H1 report for 2014

Non-Regulatory

MPI’s Lung Prognostic Chip study expanded with new gene test – publication of data consequently postponed to H1 2015

Non-Regulatory

MPI and LiPlasome present the phase 1 study with LiPlaCis at the ASCO congress Monday 2 in Chicago at 8am local time

Regulatory

MPI increases its capital by 67,774 shares as a result of the capital increase adopted on the annual general meeting held on 24 April 2014

Regulatory

MPI increases its capital by 21,500 shares as a result of employee warrant exercise

Regulatory

Medical Prognosis Institute A/S – Passing of Annual General Meeting

Regulatory

Medical Prognosis Institute A/S – Forløb af ordinær generalforsamling

Regulatory

Medical Prognosis Institute A/S -Indberetning af ledende medarbejders og nærståendes transaktioner

Regulatory

Notice of Annual General Meeting in Medical Prognosis Institute A/S

Non-Regulatory

MPI and TD2 join in strategic collaboration to provide drug developers a unique Multi Biomarker direct path to drug approval

Non-Regulatory

MPI og TD2 indgår strategisk samarbejde med henblik på at tilbyde udviklere af kræftlægemidler en unik Multi Biomarkør-tilgang til lægemiddelgodkendelse

Regulatory

Medical Prognosis Institute A/S – Annual Report 2013

Regulatory

Medical Prognosis Institute A/S – Årsregnskabsmeddelelse 2013

Non-Regulatory

MPI publishes data showing that MPI’s product DRP may help to identify patients with tumors more likely to respond to fulvestrant

Non-Regulatory

MPI offentliggør data som viser, at firmaet kan hjælpe med at finde de patienter, der har størst sandsynlighed for gavn af behandling med fulvestrant

Regulatory

Medical Prognosis Institute udsteder warrants

Non-Regulatory

MPI presents data on its Drug Response Predictor technology that can predict which indication will be approved by the FDA on the ADAPT Congress in Boston